NotizieBenzingaVanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated Benzinga 2026.10.14 21:03 (GMT+0) Apri Benzinga Altre notizie Newline by Fifth Third lancia carte Visa aziendali in oltre 40 paesi Cognizant amplia la partnership con Google Cloud con 18.000 ingegneri Alaska Airlines nomina Amaresh Siva come chief information officer Global-E Online in rialzo dopo l’upgrade di Morgan Stanley Le azioni di Match Group salgono dopo l’upgrade di Evercore ISI su Tinder World Copper acquisisce una proprietà di esplorazione aurifera in Nevada
